Table 2 Identified hepatitis C follow-up studies published in 2000 to 2009 – n = 140

Transmission (42)

Australia (5); Brazil (1); Canada (5); Chile (1); China (2); Denmark (1); Egypt (3); Germany (1); Italy (3); Japan (3); Netherlands (1); Scotland (1); Spain (1); Switzerland (1); Thailand (1); UK (3); US (9)

Endoscopy patients (1); general populations (5); hemodialysis patients (5); injecting drug users (18); men who have sex with men (2); people with HIV (3); perinatal populations (4); prisoners (4)

0.3 to 11 years

18 to 6,412

Natural history (69)

Australia (2); Canada (1); China (1); Denmark (2); Europe – 8 centres (2); France (1); Greece (1); Ireland (1); Italy (9); Japan (19); Netherlands (2); Spain (6); Sweden (3); Switzerland (1); Thailand (1); Turkey (1); Taiwan (2); UK (2); US (12)

Hepatitis C mono-infection, with/out co morbidity (41); hepatitis B and C co-infection, or cf. Mono-infection outcomes (15); hepatitis C and HIV co-infection, or cf. Mono-infection outcomes (11); hepatitis C, B and HIV co-infection, or cf. mono –infection outcomes (2);

1.0 to 35 years

17 to 474,369

Antiviral treatment related quality of life (8)

Italy (1); Sweden (1); Turkey (1); US (5)

Patients undergoing treatment (4); patients assessed pre- and post-treatment (4)

Up to 1.4 years

18 to 1,144

Health outcomes post treatment or other management (28)

Canada (4); Europe – 8 centres (1); France (1); Greece (1); Italy (2); Japan (7); Norway (1); Switzerland (2); Thailand (1); US (8)

Hepatitis C mono-infection and antiviral treatment (15); hepatitis C, hepatitis B and/or HIV co-infection – hepatitis C antiviral treatment response (4); post liver transplant patients, with/out hepatitis C antiviral treatment (9)

0.5 to14.4 years

45 to 13,855